Atara Biotherapeutics, Inc.
ATRA Healthcare Biotechnology
Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024. In the quarter to June 2026, revenue fell 96.4%, EPS fell 260.0% and free cash flow grew 52.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow ATRA
Atara Biotherapeutics, Inc. (ATRA) P/E ratio
Atara Biotherapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 8.1× (December 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 5.7× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 5.7× | (11.31%) |
| Sep 2025 | 6.5× | — |
| 18 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATRA Atara Biotherapeutics, Inc. | n/m |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| ANIX ANIXA BIOSCIENCES INC compare | n/m |
| RANI Rani Therapeutics Holdings, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| CBUS Cibus, Inc. compare | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| ICCC ImmuCell Corporation compare | 126× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)